Chemical Property of Escitalopram oxalate
Chemical Property:
- Appearance/Colour:white solid
- Melting Point:152-153 °C
- Boiling Point:428.3 °C at 760 mmHg
- Flash Point:212.8 °C
- PSA：110.86000
- LogP:2.96858
- Storage Temp.:-20°C Freezer, Under Inert Atmosphere
- Solubility.:DMSO: ≥15mg/mL
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:8
- Rotatable Bond Count:6
- Exact Mass:414.15910000
- Heavy Atom Count:30
- Complexity:537
- Purity/Quality:
-
99% *data from raw suppliers
Escitalopram oxalate *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xi
- Hazard Codes:Xi
- Statements:
36/37/38
- Safety Statements:
26-36
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O
- Isomeric SMILES:CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O
- Recent ClinicalTrials:Efficacy of Hydroxyzine for Patients With Panic Disorder
- Recent EU Clinical Trials:Investigation of SSRI induced neuroplastic changes in musicians using functional magnetic resonance imaging
-
Description
Escitalopram was launched as Cipralex? in Switzerland, Sweden and UK for
the
treatment of depression and panic disorder. It is the S-enantiomer version of the
selective serotonin reuptake inhibitor (SSRI) citalopram approved in 1989. It can be
obtained from 5cyanophthalide by successive reactions with 4-fluorophenyl magnesium
bromide and 3-(dimethylamino)propyl magnesium chloride. The resulting racemic diol can
be resolved by several routes such as crystallization with a chiral acid. Finally, a two step
cyclisation procedure affords escitalopram. Escitalopram is twice as effective as the
racemate and over 100 fold more potent than the R-enantiomer in inhibiting the 5HT
reuptake in vivo in rat brain synaptosomes. Moreover, it exhibits higher selectivity for the
human serotonin transporter relative to the noradrenaline or dopamine transporters than
any other currently available SSRl’s. In the mouse forced swim test, the duration of
immobility (which reflects antidepressant activity) for escitalopram was comparable to
citalopram and greater than (R)-citalopram. Clinical trials in patients with panic disorders or
depression have shown that escitalopram has a clinically relevant and significant effect.
Additionally, it has a faster onset of antidepressant action than citalopram. Escitalopram
has linear pharmacokinetics, with a long half-life (27-32 h). It is extensively metabolized in
the liver via cytochromes P450 to S(+)-desmethyl and S(+)-didesmethyl citalopram.
However, it has been shown to be a weak or negligible inhibitor of CYP450 drugmetabolizing
enzymes in vitro. Escitalopram is well tolerated with nausea being the most
common side effect.
-
Uses
Escitalopram oxalate may be used as a pharmaceutical primary standard for the quantification of the analyte in pharmaceutical formulations using analytical techniques. An inhibitor of serotonin (5-HT) uptake. Antidepressant A labelled inhibitor of serotonin (5-HT) uptake. Antidepressant antineoplastic
